The director of the National Institute of Allergy and Infectious Diseases said several vaccine-makers are currently performing age and dose deescalation studies to assess the vaccine’s risks and benefits for different age groups, ranging from 6 months to 12 years.
“It is likely and almost certain that by the time we get to the end of this calendar year and the first quarter of 2022, that we will have enough information regarding safety and immunogenicity to be able to vaccinate children of any age,” Dr. Fauci said.
Less than a week after the CDC recommended Pfizer’s vaccine for children ages 12 to 15, the U.S. had already vaccinated more than 600,000 kids in this age group, CDC Director Rochelle Walensky said during the same briefing.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.